{"product_id":"lemide-25-lenalidomide-3","title":"ELTROMDX 50 (Eltrombopag)","description":"Eltrombopag is used to  treat thrombocytopenia (a low blood platelet count) in adults and children with chronic immune thrombocytopenic purpura that did not get better with other treatment.\r\n\u003ch3\u003e\u003cspan id=\"Chronic_Immune_Thrombocytopenia_ITP\"\u003eChronic Immune Thrombocytopenia (ITP)\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy\r\n\r\nUse only in patients with ITP whose clinical condition increases bleeding risk\r\n\r\nInitial: 50 mg PO qDay\r\n\r\nMaintenance: Adjust dose to achieve and maintain platelet count (Plt) \u0026gt;50 x 10^9\/L to reduce risk of bleeding; not to exceed 75 mg\/day\r\n\u003ch3\u003e\u003cspan id=\"Chronic_Hepatitis_C-associated_Thrombocytopenia\"\u003eChronic Hepatitis C-associated Thrombocytopenia\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated to allow initiation and maintenance of interferon-based therapy\r\n\r\nInitial: 25 mg PO qDay\r\n\r\nAdjust dose in 25 mg increments q2weeks PRN to achieve target platelet count required to initiate\/maintain antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg\/day\r\n\r\nDuring antiviral therapy, adjust dose to avoid dose reductions of peginterferon\r\n\u003ch3\u003e\u003cspan id=\"Severe_Aplastic_Anemia\"\u003eSevere Aplastic Anemia\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"First-line_therapy\"\u003eFirst-line therapy\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst-line treatment, in combination with standard immunosuppressive therapy, for patients with severe aplastic anemia (SAA)\u003c\/li\u003e\r\n \t\u003cli\u003eInitial dose: 150 mg PO qDay for 6 months\u003c\/li\u003e\r\n \t\u003cli\u003eDo not exceed initial dose; total duration is 6 months\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Refractory_SAA\"\u003eRefractory SAA\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated for SAA in patients who fail to respond adequately to at least 1 prior immunosuppressive therapy\u003c\/li\u003e\r\n \t\u003cli\u003eInitial dose: 50 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eAdjust dose in 50-mg increments q2Weeks PRN to achieve target Plt ≥50 x 10^9\/L as necessary; not exceed 150 mg\/day; may take up to 16 weeks for hematologic response\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948231723,"sku":"RL1020230315250","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-06-0814.jpg?v=1787022110","url":"https:\/\/xomeds.com\/products\/lemide-25-lenalidomide-3","provider":"XOMEDS","version":"1.0","type":"link"}